BROOMFIELD, Colo., Sept. 12, 2026 /PRNewswire/ — Quantinuum Inc. (Nasdaq: QNT) (the "Company"), a leading quantum computing company, today announced that members of its management team will participate in the Piper Sandler 5th Annual Growth Frontiers Conference, taking place September 14–16, 2026, in Nashville, Tennessee.

Quantinuum will participate in a fireside chat and host one-on-one meetings with investors during the conference.

About Quantinuum

Quantinuum is a leading quantum computing company offering a full-stack platform designed to make quantum computing deployable in real-world environments. The company has commercially deployed multiple generations of trapped-ion based quantum systems built on the well-established QCCD architecture, which it has implemented with novel designs and capabilities to achieve the industry’s highest accuracy levels based on average two-qubit gate fidelity. Quantinuum has active engagements with market leaders across pharmaceuticals, material science, financial services, and government and industrial markets, as well as academic and research institutions globally.

The company has a global workforce of approximately 800 employees, including top scientists and researchers. Over 70% of its technology team holds PhDs or Master’s degrees. Quantinuum’s headquarters is in Broomfield, Colorado, with additional facilities across the United States, United Kingdom, Germany, Japan, Qatar, and Singapore.

Contacts

Investor & Media Contact

Shub Mukherjee – Investor Contact – investors@quantinuum.com
Aaron Sorenson – Media Contact – press@quantinuum.com 

Source link

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
You May Also Like

Shrewsbury International School Hong Kong Launches Key Stage 3 with Celebratory Ceremony

HONG KONG, March 9, 2026 /PRNewswire/ — Shrewsbury International School Hong Kong…

Everest Medicines Announces that Licensing Partner LIB Therapeutics has Received U.S. FDA Approval of LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol

SHANGHAI, Dec. 17, 2025 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, "Everest", or…

Sky Labs' Wearable Device "Apollon" Recognized as an Honoree in CES 2025 Innovation Awards

SEOUL, South Korea, Nov. 18, 2024 /PRNewswire/ — Sky Labs announced that…